HMG-CoA reductase inhibitor (statin) — withdrawn worldwide 2001-08-08 after 52 confirmed fatal rhabdomyolysis cases, predominantly attributable to coadministration with gemfibrozil. Mechanism of the fatal DDI: CYP2C8 inhibition by gemfibrozil glucuronide raises cerivastatin AUC ~6× (Backman 2002 PMID:12496749 — verbatim AUC 559% of control). Bayer paid $1.15 billion to settle lawsuits over the withdrawal. Retained in the registry for historical reference and as the canonical CYP2C8 DDI cautionary tale. PK (Baycol label + Mück 2000 PMID:10976657 review): Absolute F 60% (range 39–101%) due to presystemic first-pass, Tmax 2–3 h, terminal t½ 2–4 h, plasma protein binding >99%, apparent Vd ~0.3 L/kg (~21 L). Dual CYP2C8/CYP3A4 metabolism — the latter pathway only ~50% effective when both routes are inhibited, which is why gemfibrozil (CYP2C8 inhibitor, AUC ↑5.59× Wave 2a v1.1) and itraconazole (CYP3A4) produced lethal rhabdomyolysis combinations and led to the August 2001 worldwide withdrawal after 52 fatal cases.
Half-Life & Elimination Curve (PO: 3h)
Plasma (PO)t½ Decay (3h)
0×t½0h100%(6.62 µg/L)
1×t½3h50%(3.31 µg/L)
2×t½6h25%(1.65 µg/L)
3×t½9h12.5%(0.827 µg/L)
4×t½12h6.3%(0.414 µg/L)
5×t½15h3.1%(0.207 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)2.36h
Est. Peak (Cmax)6.62 µg/L
Clearance (CL)4.85 L/h
97% Washout (5×t½)15h
Dosing Guidelines
Oral (PO): Typical 0.4 mg (Range: 0.1–0.8 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 60% · Volume of Distribution (Vd): 21 L · Absorption (ka): 0.7 h⁻¹ (t½ka ≈ 59m) [PMID 10976657]